Opportunity Information: Apply for PA 12 110
Apply for PA 12 110
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Getting from Genes to Function in Lung Disease (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.838 Lung Diseases Research.
- This funding opportunity was created on Feb 22, 2012 and posted on Feb 22, 2012.
- Applicants must submit their applications by Sep 7, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Public and State controlled institutions of higher education County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts State governments Native American tribal organizations (other than Federally recognized tribal governments) For profit organizations other than small businesses Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Others (see text field entitled Additional Information on Eligibility for clarification) City or township governments Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Special district governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH grant opportunity "Getting from Genes to Function in Lung Disease (R01)" (Funding Opportunity Number PA-12-110) is a discretionary research grant designed to push lung disease genetics beyond discovery and into biological understanding. The central goal is to fund projects that take gene(s) and specific genetic variants flagged by genome-wide association studies (GWAS) or other human genetic approaches and then rigorously define what those genes and variants actually do in the context of lung disease. In practice, the emphasis is on moving from statistical association signals to clear pathobiological function, meaning investigators are expected to explain how implicated genes influence disease mechanisms such as airway inflammation, immune responses, tissue remodeling, epithelial or endothelial dysfunction, mucociliary clearance, fibrosis, vascular changes, or other processes relevant to lung pathology.
A key theme of the announcement is integration across scientific disciplines rather than relying on a single method or viewpoint. Competitive applications would typically combine human genetics with functional genomics, molecular and cell biology, computational biology, bioinformatics, systems biology, and disease-relevant experimental models. The FOA is aimed at studies that can connect a variant to a gene, a gene to a pathway, and a pathway to a measurable disease-related phenotype. That often includes work such as fine-mapping and prioritization of candidate causal variants, determining regulatory effects on gene expression (for example, eQTL-style logic in disease-relevant lung cell types), testing allele-specific function, and validating mechanisms in appropriate cellular systems or animal models. The overall expectation is that the proposed work will clarify biological causality and mechanism, not just replicate associations or generate additional correlation-based datasets.
The funding mechanism is an NIH R01, which generally supports substantial, hypothesis-driven research programs with clear aims, strong rationale, and well-justified experimental plans. The activity falls under CFDA 93.838 (Lung Diseases Research). The opportunity does not require cost sharing or matching, which means applicants are not expected to commit institutional funds as a condition of award. The announcement was posted and created on February 22, 2012, with an original and current closing date of September 7, 2012, and an archive date of October 8, 2012, indicating it is no longer open but remains a useful reference point for similar NIH initiatives.
Eligibility is broad and includes most major categories of research-performing organizations. Eligible applicants listed include public and private institutions of higher education, nonprofit organizations with or without 501(c)(3) status, for-profit organizations (including small businesses and for-profits other than small businesses), and a wide range of governmental entities (state governments, county governments, city or township governments, special district governments, and independent school districts). The FOA also explicitly includes tribal governments and tribal organizations (both federally recognized and other than federally recognized), public housing authorities/Indian housing authorities, and regional organizations. It further notes eligibility for Alaska Native and Native Hawaiian Serving Institutions, Hispanic-Serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs), as well as faith-based or community-based organizations and eligible federal agencies. Importantly, foreign institutions are eligible to apply, non-U.S. components of U.S. organizations are eligible, and foreign components are allowed as defined by NIH policy, which opens the door to international collaborations when justified by expertise, cohorts, or specialized resources.
From a project design perspective, the FOA is fundamentally about functional follow-through. It supports research that can explain why a GWAS locus matters, identify the gene(s) truly responsible at that locus when the signal is noncoding or spans multiple genes, and demonstrate the downstream consequences in lung biology. Strong applications would typically show a convincing chain of evidence linking variant to molecular function (for example, altered transcription factor binding, enhancer activity, splicing, or protein function), to cellular phenotype in relevant lung cell populations, and ultimately to disease-relevant outcomes. The use of integrated approaches implies that NIH is looking for teams or plans that can bridge data types and experimental levels, such as pairing human cohort genetic signals with mechanistic assays, multi-omics integration, and functional perturbation experiments.
The sponsoring agency is the National Institutes of Health. The full archived announcement is referenced through the NIH Grants Guide link: http://grants.nih.gov/grants/guide/pa-files/PA-12-110.html. For technical issues accessing the announcement or link problems, the contact listed is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Frequently Asked Questions (FAQs): Getting from Genes to Function in Lung Disease (R01) - PA-12-110
What is the main purpose of this NIH funding opportunity?
The purpose of "Getting from Genes to Function in Lung Disease (R01)" (PA-12-110) is to move lung disease genetics beyond discovery and into biological understanding. It is focused on projects that take gene(s) and specific genetic variants identified by GWAS or other human genetic approaches and then define what those genes and variants actually do in the context of lung disease.
What does "getting from genes to function" mean in practical terms for this FOA?
In practical terms, it means progressing from a statistical association signal (such as a GWAS hit) to clear pathobiological function. Applicants are expected to explain how implicated genes or variants influence lung-disease-relevant mechanisms, rather than only reporting correlations or additional association signals.
What kinds of lung disease mechanisms are specifically relevant to this opportunity?
The FOA highlights mechanisms such as airway inflammation, immune responses, tissue remodeling, epithelial or endothelial dysfunction, mucociliary clearance, fibrosis, vascular changes, and other processes relevant to lung pathology.
What types of genetic findings are intended as starting points for projects?
The intended starting points include gene(s) and specific genetic variants flagged by genome-wide association studies (GWAS) or other human genetic approaches. The emphasis is on functional follow-through from those human genetic signals.
Does the FOA prioritize mechanism over discovery?
Yes. The FOA is centered on clarifying biological causality and mechanism. It explicitly emphasizes moving beyond replicating associations or generating additional correlation-based datasets and instead demonstrating what a variant or gene does biologically in lung disease.
What kinds of approaches are considered competitive for this FOA?
Competitive applications typically integrate multiple disciplines and methods, often combining human genetics with functional genomics, molecular and cell biology, computational biology, bioinformatics, systems biology, and disease-relevant experimental models.
What does the FOA mean by an "integrated" research approach?
Integration here means connecting multiple layers of evidence, such as linking a variant to a gene, a gene to a pathway, and a pathway to a measurable disease-related phenotype. It also implies bridging data types and experimental levels rather than relying on a single method or viewpoint.
What is the expected evidence chain in a strong application?
Strong applications typically aim to show a convincing chain of evidence from variant to molecular function (for example, altered transcription factor binding, enhancer activity, splicing, or protein function), to cellular phenotypes in relevant lung cell populations, and ultimately to disease-relevant outcomes.
Are studies that only replicate GWAS findings responsive to this FOA?
The FOA indicates the overall expectation is to clarify biological causality and mechanism, not simply replicate associations or produce additional correlation-based datasets. Projects should focus on functional interpretation and mechanistic validation.
What are examples of study activities that align with this FOA?
Examples mentioned or implied include fine-mapping and prioritization of candidate causal variants, determining regulatory effects on gene expression in disease-relevant lung cell types (eQTL-style logic), testing allele-specific function, and validating mechanisms in appropriate cellular systems or animal models.
How does the FOA address noncoding signals or loci spanning multiple genes?
The FOA supports research designed to explain why a GWAS locus matters, identify the gene(s) truly responsible when the signal is noncoding or spans multiple genes, and demonstrate downstream consequences in lung biology.
What funding mechanism is used for this opportunity?
This opportunity uses the NIH R01 mechanism, which generally supports substantial, hypothesis-driven research programs with clear aims, strong rationale, and well-justified experimental plans.
What is the CFDA number associated with this FOA?
The activity is listed under CFDA 93.838 (Lung Diseases Research).
Is cost sharing or matching required?
No. The FOA states that cost sharing or matching is not required, meaning applicants are not expected to commit institutional funds as a condition of award.
When was this funding opportunity posted, and what are the closing dates?
The announcement was posted and created on February 22, 2012. The original and current closing date listed is September 7, 2012. The archive date is October 8, 2012.
Is this FOA currently open for applications?
No. Based on the listed closing date (September 7, 2012) and the archive date (October 8, 2012), it is no longer open. It remains available as an archived reference for similar NIH initiatives.
Who is the sponsoring agency?
The sponsoring agency is the National Institutes of Health (NIH).
What organizations are eligible to apply?
Eligibility is broad and includes public and private institutions of higher education; nonprofit organizations with or without 501(c)(3) status; for-profit organizations (including small businesses and for-profits other than small businesses); and many governmental entities, including state, county, city or township, special district governments, independent school districts, and regional organizations.
Are tribal governments and tribal organizations eligible?
Yes. The FOA explicitly includes tribal governments and tribal organizations, including those that are federally recognized and those other than federally recognized.
Are public housing authorities eligible?
Yes. Public housing authorities/Indian housing authorities are listed as eligible applicants.
Are minority-serving institutions specifically included in the eligibility list?
Yes. The FOA notes eligibility for Alaska Native and Native Hawaiian Serving Institutions, Hispanic-Serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs).
Are faith-based or community-based organizations eligible?
Yes. The FOA includes faith-based or community-based organizations among eligible applicants.
Are foreign institutions allowed to apply?
Yes. The FOA states that foreign institutions are eligible to apply.
Can a U.S. organization include non-U.S. components in the project?
Yes. The FOA states that non-U.S. components of U.S. organizations are eligible.
Are foreign components permitted under NIH policy?
Yes. The FOA states that foreign components are allowed as defined by NIH policy, supporting international collaborations when justified by expertise, cohorts, or specialized resources.
Where can the full (archived) announcement be found?
The archived announcement is referenced through the NIH Grants Guide at: http://grants.nih.gov/grants/guide/pa-files/PA-12-110.html
Who should be contacted for technical issues accessing the announcement or link problems?
For technical issues or link problems, the contact listed is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same category: Health
Next opportunity: Limited Competition for the Continuation of the Clinical Centers for The Environmental Determinants of Diabetes in the Young (TEDDY) Study (UC4)
Previous opportunity: BJA FY 12 Anti Human Trafficking Training and Technical Assistance for Tribal Law Enforcement
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 12 110
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 12 110) also looked into and applied for these:
| Funding Opportunity |
|---|
| Part C Capacity Development Program Apply for HRSA 12 077 Funding Number: HRSA 12 077 Agency: Health Resources and Services Administration Category: Health Funding Amount: $100,000 |
| Infrastructure Development Program in Patient Centered Outcomes Research (PCOR) (R24) Apply for PA 12 114 Funding Number: PA 12 114 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $250,000 |
| Rural Health Research Center Cooperative Agreement Apply for HRSA 12 164 Funding Number: HRSA 12 164 Agency: Health Resources and Services Administration Category: Health Funding Amount: $660,000 |
| Telehealth Network Grant Program Apply for HRSA 12 092 Funding Number: HRSA 12 092 Agency: Health Resources and Services Administration Category: Health Funding Amount: $250,000 |
| Telehealth Resource Center Grant Program Apply for HRSA 12 097 Funding Number: HRSA 12 097 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Patient Centered Outcomes Research Dissemination by Health Professionals Associations (PCOR DHPA) (R18) Apply for RFA HS 12 006 Funding Number: RFA HS 12 006 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $300,000 |
| Engaging Local Indigenous Organizations in Developing HIV/AIDS Monitoring and Evaluation Capacity in Ukraine under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH12 1228 Funding Number: CDC RFA GH12 1228 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $800,000 |
| Field Triage of Traumatic Brain Injury (TBI) in Older Adults Taking Anticoagulants or Platelet Inhibitors Apply for RFA CE 12 005 Funding Number: RFA CE 12 005 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $250,000 |
| Improving the Health of People with Disabilities through State Based Public Health Programs Apply for CDC RFA DD12 1204 Funding Number: CDC RFA DD12 1204 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $300,000 |
| State Heart Disease and Stroke Prevention Programs Apply for CDC RFA DP07 7040501SUPP12 Funding Number: CDC RFA DP07 7040501SUPP12 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Characterizing the Short and Long Term Consequences of Traumatic Brain Injury (TBI) among Children in the United States Apply for RFA CE 12 004 Funding Number: RFA CE 12 004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $550,000 |
| Alcohol related Motor Vehicle Injury Research Apply for RFA CE 12 006 Funding Number: RFA CE 12 006 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| Research to Prevent Prescription Drug Overdoses Apply for RFA CE 12 007 Funding Number: RFA CE 12 007 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| Health Promotion for People with Disabilities Apply for CDC RFA DD07 7020501SUPP12 Funding Number: CDC RFA DD07 7020501SUPP12 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Nurse Anesthetist Traineeship Program (NAT) Apply for HRSA 12 063 Funding Number: HRSA 12 063 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| AHRQ Mentored Career Enhancement Award in Patient Centered Outcomes Research (PCOR) for Mid Career and Senior Investigators (K18) Apply for PAR 12 115 Funding Number: PAR 12 115 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $275,000 |
| PPHF 2012 Community Transformation Grants financed solely by 2012 Public Prevention Health Fund Apply for CDC RFA DP11 1103PPHF1102CONT12 Funding Number: CDC RFA DP11 1103PPHF1102CONT12 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Research Networks for Macromolecular Interactions in Cells (U54) Apply for RFA GM 13 005 Funding Number: RFA GM 13 005 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Collaborations for Macromolecular Interactions in Cells (R01) Apply for RFA GM 13 004 Funding Number: RFA GM 13 004 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Paul Coverdell National Acute Stroke Program Apply for CDC RFA DP12 1203 Funding Number: CDC RFA DP12 1203 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $600,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 12 110", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.